RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on BioCryst, with a price target of $13.00.

Claim 30% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Abrahams covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, BioCryst, and Regeneron. According to TipRanks, Abrahams has an average return of 7.3% and a 48.50% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $21.63 average price target.

Based on BioCryst’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $406.56 million and a net profit of $245.85 million. In comparison, last year the company earned a revenue of $131.53 million and had a GAAP net loss of $26.8 million

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Earlier this month, THERESA HEGGIE, a Director at BCRX sold 49,933.00 shares for a total of $504,822.63.